Navigation Links
Cornerstone Pharmaceuticals to Present New Data on CPI-613 at the American Society of Hematology 2016 Annual Meeting
Date:11/21/2016

CRANBURY, N.J., Nov. 21, 2016 /PRNewswire/ --

WHAT: CPI-613 is Cornerstone Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism. It selectively targets the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell proliferation and survival. The two datasets are from the first reported studies of CPI-613-based combination therapies in patients with AML and T-cell NHL. 

ASH Abstract Details:

  • TCA Cycle Inhibition by CPI-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)
    • Date/Time: Monday, December 5, 2016 6:00-8:00 PM PT
    • Session: 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster III
    • Location: San Diego Convention Center, Hall GH
    • Abstract #: 4062
    • Scheduled Presenter: Timothy S. Pardee, M.D. Ph.D., Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, N         
  • Phase I Dose-Escalation Study of CPI-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
    • Date/Time: Monday, December 5, 2016, 6:00-8:00 PM PT
    • Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
    • Location: San Diego Convention Center, Hall GH
    • Abstract #: 4163
    • Scheduled Presenter: Zanetta S. Lamar, M.D., Department of Hematology / Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC

WHO: Drs. Pardee and Lamar (primary investigators) will be available for media interviews upon request

WHERE: American Society of Hematology Annual Meeting, San Diego Convention Center, San Diego, California

CONTACT: Kara Golub, 609-456-0822 or kgolub@jfkhealth.com, for more information.

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a privately held, clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's investors include IDT Corporation (NYSE: IDT). Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS).www.cornerstonepharma.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-to-present-new-data-on-cpi-613-at-the-american-society-of-hematology-2016-annual-meeting-300366293.html


'/>"/>
SOURCE Cornerstone Pharmaceuticals
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon
2. HelpMeSee & Cornerstone Assistance Showcase MSICS In Texas
3. Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by Chiesi Farmaceutici S.P.A. Encouraged to Contact Lawyers at Deans & Lyons
4. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
6. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017
7. Atrin Pharmaceuticals Elects Jeffrey M. Dayno, MD to Board of Directors
8. FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
9. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
10. Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx
11. Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... The National Comprehensive ... Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR to ... NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with CureMD ...
(Date:6/11/2019)... ... 2019 , ... SABRE , the leading brand in personal safety and ... showcase their latest and most innovative personal safety products, including the Mighty Discreet ... Summer Market 2019 (Booth #39158-UL), June 18-20 in Denver, CO. , SABRE’s ...
(Date:6/6/2019)... OAKLAND, Calif. (PRWEB) , ... June 06, 2019 , ... ... to further curtail US travel to Cuba. “This latest move is one more assault ... the island,” said Dr. Peter G. Bourne, Chair of MEDICC’s Board of Directors. ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School of Health and ... Informatics (MSHI ) degree program to address the growing need for professionals who can ... of a larger effort for SHRS to bring more graduate degrees online. The Master ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... tissue fabrication, patient-matched models and surgical guides, and prosthetics and assistive devices—are ... patient care. Children with birth defects, soldiers with cranial injuries, conjoined twins, ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... with caregivers and dementia patients to deteriorate. , Researchers from the University ... survey with professional caregivers who care for people who have dementia and experienced ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... Miller, a quality assurance expert with more than 25 years of experience in ... Compliance for all classes of medical devices, has joined NDA Partners as an ...
(Date:6/12/2019)... ... 12, 2019 , ... In September of 2018, NVNA and Hospice (NVNA) partnered ... patient monitoring. Following its full-scale launch in March, NVNA has expanded its program with ... of 2019, NVNA has achieved an average all-cause hospital readmissions rate of 7.3% and ...
Breaking Medicine News(10 mins):